400
Participants
Start Date
February 3, 2023
Primary Completion Date
December 15, 2032
Study Completion Date
December 15, 2032
Somapacitan
Sogroya therapy in participants with AGHD.
UKC Ljubljana, Endocrinology and Diabetes, Ljubljana
NYU Langone Health, New York
Cornell University, New York
St Lukes Physician Group, Center Valley
Johns Hopkins University, Baltimore
Medicover MVZ Oldenburg, Oldenburg
Medicover Oldenburg MVZ, Oldenburg
University of North Carolina, Chapel Hill
Physicians East Endocrinology, Greenville
Atlanta Diabetes Associates, Atlanta
Uniklinik Aachen - Endokrinologie und Diabetologie, Aachen
Universitätsmedizin der JGU Mainz - Endokrinologie und Stoffwechselerkrankungen, Mainz
CHU LILLE - HOPITAL CLAUDE HURIEZ - Service d'endocrinologie et diabétologie, Lille
King Fahad Medical City, Riyadh
Endokrinologikum Frankfurt, Frankfurt am Main
Washington University, St Louis
UNMC, Omaha
HCL - HOPITAL LOUIS PRADEL - Service d'endocrinologie, Bron
APHP - LA PITIE SALPETRIERE - Service endrocrinologie et medecine de la reproduction, Paris
Revival Research Institute, LLC, Dallas
Consano Clinical Research, LLC, Shavano Park
EP Premier Medical Group PA, El Paso
Anschutz Outpatient Pavilion, Aurora
LMU Klinikum Großhadern München - Med. Klinik, München
Medicover Neuroendokrinologie MVZ München, München
Medicover Neuroendokrinologie MVZ, München
Barrow Neurological Institute, Phoenix
Palm Research Center Inc-Vegas, Las Vegas
Northern Nevada Endocrinology, Reno
Keck Medical Center of USC - Outpatient Clinic, Los Angeles
UCLA Health, Los Angeles
Advanced Rx Clinical Research, Westminster
Stanford Univ School of Med, Palo Alto
Universitätsklinikum Würzburg - Zentrum für Innere Medizin (ZIM), Würzburg
Oregon Health & Science University, Portland
Tufts Medical Center, Boston
Massachusetts General Hospital, Boston
Brigham & Women's Hospital, Boston
Puget Sound VA, University of Washington, Seattle
Universitätsklinikum Halle - Innere Medizin III, Halle
Fukuoka University Chikushi Hospital_Endocrinology and Diabetes Mellitus, Chikushino-shi, Fukuoka
Kagoshima University Hospital_Neurosurgery, Kagoshima-shi, Kagoshima
Nippon Medical School Musashikosugi Hospital_Neurological Surgery, Kawasaki-shi, Kanagawa
Kobe University Hospital_Diabetes and Endocrinology, Kobe-shi, Hyogo
Okayama University Hospital_General Medicine, Okayama-shi, Okayama
Osaka City General Hospital_Endocrinology and Diabetes Mellitus, Osaka-shi, Osaka
Lead Sponsor
Novo Nordisk A/S
INDUSTRY